Companies / Regeneron
Regeneron
Company- Related drugs
- 6
- Related conditions
- 9
Recent developments
| Alnylam Q4 Earnings Beat, Revenue Misses on 85% Growth; Stock Down 4.1% | genengnews.com ↗ | |
| Biocon and Zydus Launch Aflibercept Biosimilars for Retinal Diseases | healio.com ↗ | |
| WHO Launches Clinical Trial for Bundibugyo Ebola Treatments in DRC | idse.net ↗ | |
| Ocular Therapeutix Stock Surges 30% Ahead of AXPAXLI Wet AMD Phase 3 Data Release | ophthalmologytimes.com ↗ | |
| FAERS Analyses Uncover Diverse Drug Safety Risks Across Therapeutic Areas | cureus.com ↗ | |
| Regeneron, Parabilis Partner on Antibody-Helicon Conjugates in Deal Worth Up to $2.3 Billion | insideprecisionmedicine.com ↗ | |
| European Biotechs Advance Next-Generation Immunotherapy Targets Beyond PD-1/PD-L1 | pharmtech.com ↗ | |
| CRISPR Therapies for Alpha-1 Antitrypsin Deficiency Advance with New Data and FDA Designations | crisprmedicinenews.com ↗ | |
| Novartis' Rhapsido Gets EU Approval for CSU, Shows Promise in CINDU Phase 3 Trial | pharmaphorum.com ↗ | |
| Trump Imposes 100% Tariffs on Drugmakers Without Price Deals | swissinfo.ch ↗ |
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.